These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 19924383)
1. MEPE evolution in mammals reveals regions and residues of prime functional importance. Bardet C; Delgado S; Sire JY Cell Mol Life Sci; 2010 Jan; 67(2):305-20. PubMed ID: 19924383 [TBL] [Abstract][Full Text] [Related]
2. Adaptive evolution of the matrix extracellular phosphoglycoprotein in mammals. Machado JP; Johnson WE; O'Brien SJ; Vasconcelos V; Antunes A BMC Evol Biol; 2011 Nov; 11():342. PubMed ID: 22103247 [TBL] [Abstract][Full Text] [Related]
3. Active sites of human MEPE-ASARM regulating bone matrix mineralization. Minamizaki T; Sakurai K; Hayashi I; Toshishige M; Yoshioka H; Kozai K; Yoshiko Y Mol Cell Endocrinol; 2020 Nov; 517():110931. PubMed ID: 32712387 [TBL] [Abstract][Full Text] [Related]
4. MEPE is a novel regulator of growth plate cartilage mineralization. Staines KA; Mackenzie NC; Clarkin CE; Zelenchuk L; Rowe PS; MacRae VE; Farquharson C Bone; 2012 Sep; 51(3):418-30. PubMed ID: 22766095 [TBL] [Abstract][Full Text] [Related]
5. Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin. Boukpessi T; Gaucher C; Léger T; Salmon B; Le Faouder J; Willig C; Rowe PS; Garabédian M; Meilhac O; Chaussain C Am J Pathol; 2010 Aug; 177(2):803-12. PubMed ID: 20581062 [TBL] [Abstract][Full Text] [Related]
6. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Martin A; David V; Laurence JS; Schwarz PM; Lafer EM; Hedge AM; Rowe PS Endocrinology; 2008 Apr; 149(4):1757-72. PubMed ID: 18162525 [TBL] [Abstract][Full Text] [Related]
7. Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif. Zelenchuk LV; Hedge AM; Rowe PS Bone; 2015 Oct; 79():131-42. PubMed ID: 26051469 [TBL] [Abstract][Full Text] [Related]
8. Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Rowe PS; Garrett IR; Schwarz PM; Carnes DL; Lafer EM; Mundy GR; Gutierrez GE Bone; 2005 Jan; 36(1):33-46. PubMed ID: 15664000 [TBL] [Abstract][Full Text] [Related]
9. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Rowe PS Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660 [TBL] [Abstract][Full Text] [Related]
10. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. Addison WN; Nakano Y; Loisel T; Crine P; McKee MD J Bone Miner Res; 2008 Oct; 23(10):1638-49. PubMed ID: 18597632 [TBL] [Abstract][Full Text] [Related]
11. The dentin matrix acidic phosphoprotein 1 (DMP1) in the light of mammalian evolution. Silvent J; Sire JY; Delgado S J Mol Evol; 2013 Feb; 76(1-2):59-70. PubMed ID: 23361408 [TBL] [Abstract][Full Text] [Related]
12. Variants affecting diverse domains of MEPE are associated with two distinct bone disorders, a craniofacial bone defect and otosclerosis. Schrauwen I; Valgaeren H; Tomas-Roca L; Sommen M; Altunoglu U; Wesdorp M; Beyens M; Fransen E; Nasir A; Vandeweyer G; Schepers A; Rahmoun M; van Beusekom E; Huentelman MJ; Offeciers E; Dhooghe I; Huber A; Van de Heyning P; Zanetti D; De Leenheer EMR; Gilissen C; Hoischen A; Cremers CW; Verbist B; de Brouwer APM; Padberg GW; Pennings R; Kayserili H; Kremer H; Van Camp G; van Bokhoven H Genet Med; 2019 May; 21(5):1199-1208. PubMed ID: 30287925 [TBL] [Abstract][Full Text] [Related]
13. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. Atkins GJ; Rowe PS; Lim HP; Welldon KJ; Ormsby R; Wijenayaka AR; Zelenchuk L; Evdokiou A; Findlay DM J Bone Miner Res; 2011 Jul; 26(7):1425-36. PubMed ID: 21312267 [TBL] [Abstract][Full Text] [Related]
14. Molecular regulation of matrix extracellular phosphoglycoprotein expression by bone morphogenetic protein-2. Cho YD; Yoon WJ; Woo KM; Baek JH; Lee G; Cho JY; Ryoo HM J Biol Chem; 2009 Sep; 284(37):25230-40. PubMed ID: 19617624 [TBL] [Abstract][Full Text] [Related]
15. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Rowe PS; de Zoysa PA; Dong R; Wang HR; White KE; Econs MJ; Oudet CL Genomics; 2000 Jul; 67(1):54-68. PubMed ID: 10945470 [TBL] [Abstract][Full Text] [Related]
16. Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia. Imanishi Y; Hashimoto J; Ando W; Kobayashi K; Ueda T; Nagata Y; Miyauchi A; Koyano HM; Kaji H; Saito T; Oba K; Komatsu Y; Morioka T; Mori K; Miki T; Inaba M J Bone Miner Metab; 2012 Jan; 30(1):93-9. PubMed ID: 21739089 [TBL] [Abstract][Full Text] [Related]
17. Wnt3a stimulates Mepe, matrix extracellular phosphoglycoprotein, expression directly by the activation of the canonical Wnt signaling pathway and indirectly through the stimulation of autocrine Bmp-2 expression. Cho YD; Kim WJ; Yoon WJ; Woo KM; Baek JH; Lee G; Kim GS; Ryoo HM J Cell Physiol; 2012 Jun; 227(6):2287-96. PubMed ID: 22213482 [TBL] [Abstract][Full Text] [Related]
18. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. Hayashibara T; Hiraga T; Yi B; Nomizu M; Kumagai Y; Nishimura R; Yoneda T J Bone Miner Res; 2004 Mar; 19(3):455-62. PubMed ID: 15040834 [TBL] [Abstract][Full Text] [Related]